Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

This review discusses the roles estrogens play in males and androgens in females, challenging the traditional view of strictly "male" and "female" hormones, but it does not report new experimental findings.

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.

This study found that women with polycystic ovary syndrome have a higher prevalence of non-alcoholic fatty liver disease and increased androgen bioavailability may be involved alongside metabolic factors.

This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.

This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.

Early hair loss may indicate risk of insulin resistance.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

This study found that women with polycystic ovary syndrome have higher rates of nonalcoholic fatty liver disease, with androgen excess contributing to the risk.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This review discusses the role of genetic mutations and environmental endocrine disruptors in insufficient androgen action, which can result in conditions like hypospadias, cryptorchidism, and micropenis, during male fetal development.

Hair loss linked to higher heart disease risk in both men and women.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This case report describes a young woman with hypopituitarism who experienced hair loss typical of female androgenetic alopecia without detectable androgens, suggesting this hair loss pattern may not always be androgen dependent.

This study found that reducing testosterone levels in male mice accelerates wound healing and decreases inflammation, suggesting a potential therapeutic target for improving wound repair in elderly males.

This pilot study suggests injecting platelet-derived growth factors into the scalp may offer some clinical benefits for androgenetic alopecia, though further randomized trials are needed for confirmation.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This study found that androgens, specifically DHT, induced neurite outgrowth in motor neurons by up-regulating the neuritin protein, with testosterone being less effective.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

Photographic documentation crucial for evaluating hair growth in androgenetic alopecia.

In this study, researchers found that androgenetic alopecia significantly harms quality of life, particularly in younger patients, those with more severe or long-term alopecia, and those who have sought non-medical hair care.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This commentary discusses the potential use of testosterone therapy for various conditions in women and reports no new clinical results; the authors advocate for more discussion and research in this area.

This paper discusses polycystic ovary syndrome with a focus on androgen excess as the primary symptom and notes that insulin resistance may contribute to it in many patients, but provides no new research findings.